Related Experiment Video
Updated: Apr 12, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Do Stage I Patients Need Systemic Therapy?
Stella T Tsui1, Nanruoyi Zhou1, David R Jones1
1Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract:
Surgery has been the primary treatment modality for patients with stage I non-small cell lung cancer (NSCLC) with limited to no role for adjuvant systemic therapy. However, 10% to 30% of patients with completely resected stage I NSCLC will recur, with higher risk of recurrence in tumors with higher maximum standardized uptake value, lymphovascular invasion, visceral pleural invasion, and International Association for the Study of Lung Cancer grade. Forthcoming trials of targeted therapies and immunotherapies may expand the role of adjuvant systemic therapy for patients with stage I NSCLC in the future.
More Related Videos
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

